CVAC
CurevacยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CVAC
Curevac N.V.
A biopharmaceutical company that develops mRNA-based vaccines and therapies for infectious diseases and cancer treatments
Friedrich-Miescher-Strasse 15, 72076, Tubingen, Germany
--
Curevac N.V. was incorporated under the laws of the Netherlands on April 7, 2020. The company is a global clinical-stage biopharmaceutical company developing novel translational drugs based on messenger ribonucleic acid that have the potential to improve people's lives.
Company Financials
EPS
CVAC has released its 2023 Q3 earnings. EPS was reported at -0.24, versus the expected -0.28, beating expectations. The chart below visualizes how CVAC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CVAC has released its 2025 Q3 earnings report, with revenue of 63.53M, reflecting a YoY change of -88.46%, and net profit of 320.63M, showing a YoY change of -14.89%. The Sankey diagram below clearly presents CVAC's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
